ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Celecoxib

Also written as “celecoxib”, “Celecoxib 200mg” and “Celecoxib + Acetaminophen”.

Its studies are mostly in Osteoarthritis · Osteoarthritis, Knee · Low Back Pain · Migraine Disorders · Pain, Postoperative, led by 16 companies.

Drug pageCelecoxib: every studyMany companies study it; this page follows only the 66 they lead. All 383 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 26, 200566 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatrisits history only320 open or runningphase 4since Aug 26, 2005Aug 26, 2005none ahead
Pfizerits history only100 open or runningphase 4since Sep 9, 2005May 8, 2002none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 2since Jun 8, 2015Jun 8, 2015none ahead
NeuroSense Therapeuticsits history only40 open or runningphase 2since Nov 13, 2019Aug 29, 2019none ahead
Leidos Life Sciencesits history only30 open or runningphase 2since Oct 7, 2021Oct 7, 2021none ahead
BioDelivery Sciences Internationalits history only20 open or runningphase 3since Dec 27, 2016Dec 27, 2016none ahead
Laboratorios Silanes S.A. de C.V.its history only20 open or runningphase 3since Jun 26, 2024Jun 26, 2024none ahead
Aralez Pharmaceuticalsits history only10 open or runningphase 1since Aug 5, 2008Aug 5, 2008none ahead
Arthritis Innovationits history only10 open or runningphase 2since May 8, 2018May 8, 2018none ahead
Astellas Pharmaits history only10 open or runningphase 3since May 5, 2010May 5, 2010none ahead
Chong Kun Dang Pharmaceutical10 open or runningphase 4since Feb 3, 2017Feb 3, 2017none ahead

Also a collaborator on its studies: AstraZeneca.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chong Kun Dang Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 3, 2017First study: phase 4 study in Osteoarthritis HandFirst studyNCT03067194 · 117 enrolled · Korea, Republic of

TargetBeta

PTGS2 →read by rule
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule

Other programs on PTGS2

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
MeloxicamruleBoehringer Ingelheimphase 467
EtoricoxibruleOrganonphase 435
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

The one study Chong Kun Dang Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03067194Osteoarthritis Hand · Korea, Republic of4CompletedJul 10, 2017117

How it is read

Names in the registry

  • “Celecoxib”, 49 entries
  • “celecoxib”, 7 entries
  • “Celecoxib 200mg”, 3 entries
  • “Celecoxib + Acetaminophen”, 2 entries
  • “Comparator: celecoxib”, 2 entries

Codes read as this program: DFN15.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.